Sleep Apnea Devices Market Size, Share & Covid-19 Impact Analysis, By Device Type (Therapeutic Devices, and Diagnostic Devices), By End User (Sleep Laboratories & Clinics, and Homecare & Other Settings), and Regional Forecast, 2020-2027

The global sleep apnea devices market size was USD 7.81 billion in 2019 and is projected to reach USD 13.24 billion by 2027, exhibiting a CAGR of 6.8% during the forecast period.

This report covers COVID-19 impact analysis on Sleep Apnea Devices Market

Inquire before buying

Sleep apnea is referred to as a sleep disorder that can be potentially serious, wherein the breathing of an individual demonstrates an abnormal pattern. People with untreated sleep apnea experience interrupted breathing in their sleep, due to lack of oxygen supply to the brain and the rest of the body parts. This condition is observed to be more common among elderly patients, and people suffering from diseases like diabetes, hypertension, and cardiovascular disorders, etc. Globally, obstructive sleep apnea (OSA) is the most prevalent type of sleep apnea, and to prevent this, early diagnosis and use of therapeutic devices are essential. For instance, according to the data published by Sleep Review, approximately 1 billion people across the world were suffering from sleep apnea in 2018. Thus, globally increasing incidence of sleep apnea coupled with the rising geriatric population and associated comorbidities, is expected to fuel the demand for treatment and subsequently, will boost the growth of the market during the forecast period. Also, the COVID-19 global pandemic has presented unprecedented challenges to sleep apnea devices market growth in 2020.

LATEST TRENDS

Request a sample to learn more about this report.

Introduction of New Alternative Devices for Sleep Apnea Management to Fuel the Market Growth

The shift of patients towards new advanced devices has been pivotal in the development of new alternatives for sleep apnea management. For instance, the adoption of oral appliances such as the Mandibular advancement device (MAD) for the treatment of OSA has increased due to the discomfort caused by CPAP devices in patients. Also, according to the data published by NCBI based on various studies conducted in different countries, it is estimated that the compliance rate for CPAP devices among users has declined by up to 50.0%, and this has led to launch of alternatives like oral appliances in the market that have proved to be effective and offer comfort to patients during the treatment of sleep apnea.

Along with this, actometer, a diagnostic portable device has gained huge popularity among sleep clinics due to its non-invasive nature and low cost in comparison to the traditional polysomnography devices (PSG). Hence, increasing non-adherence for CPAP devices coupled with high demand for cost-effective diagnostic devices is propelling the shift of patients towards oral appliances and actometers for effective management of sleep apnea.

COVID-19 Pandemic to Impact the Growth of the Global Market

The outbreak of COVID-19 pandemic has severely affected the management of sleep apnea patients worldwide. Several medical organizations like the European Respiratory Society, and American Academy of Sleep Medicine has recommended the use of telehealth and has provided guidelines to all sleep centers to postpone and reschedule the in-laboratory administration of PAP therapy and polysomnography, except in emergency cases. For instance, according to the data published by the European Respiratory Journal, it has been observed that prior to pandemic, laboratory based PSG was performed regularly in around 92.5% of centers, but now this procedure is been performed only in 20% centers of Europe. Also, laboratory based CPAP or bi-level therapy were practiced in almost all centers, but now less than one fifth of these centers continued this routine. Thus, reduction in these procedures among sleep centers can result in a decline in diagnosis of new sleep apnea patients during COVID-19 pandemic and can exert a negative impact on the growth of sleep apnea market in 2020.

DRIVING FACTORS

Growing Prevalence of Sleep Apnea to Spur Demand for Devices

According to the data published by Oventus, around 3 million adults in the U.S were suffering from sleep apnea in 2019. The sedentary lifestyle of people has led to an rising prevalence of cardiovascular diseases, poor sleep patterns, elevated stress, and obesity. For instance, according to the British Lung Foundation, in 2015, an estimated 40.0% of people with obesity in the U.K., were also suffering from obstructive sleep disorders (OSA). Also, according to the data published by the European Respiratory Society, approximately 13.0% to 32.0% of the geriatric population in Europe was suffering from sleep apnea. Hence, increasing prevalence of obesity and rising geriatric population, is leading to a higher incidence of sleep apnea globally. This is presenting a large patient pool requiring diagnosis and treatment for sleep apnea, driving the growth of the market. The above factors, coupled with the presence of a large pool of undiagnosed patients, and government initiatives to promote diagnosis, is expected to boost the demand for diagnostic devices and subsequently, and drive the growth of the market during the forecast period.

RESTRAINING FACTORS

High Cost of Devices to Restrict the Growth of the Market

Despite the increasing prevalence of sleep apnea and sedentary lifestyle-related conditions globally, certain factors are restricting the growth of the market. Among them is the high cost associated with devices. The CPAP and PSG devices are the preferred choices for OSA management. In countries like the U.S., and European countries, the cost of such devices is either reimbursed or covered by medical insurance companies. Whereas, in emerging countries conditions are unfavorable due to minimal medical coverage provided by public or private insurance companies. Also, the lack of awareness about obstructive sleep apnea (OSA) in emerging countries is a major factor expected to restrain the growth of the market during the forecast period.

SEGMENTATION

By Device Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Diagnostic devices to Grow at Higher CAGR during 2020-2027 Period

In terms of device type, the market is segmented into therapeutic devices, and diagnostic devices. The therapeutic device segment dominated the market in 2019. The positive airway pressure (PAP) devices are the most common devices used for the treatment of sleep apnea. Among the PAP devices, continuous positive airway pressure (CPAP) devices are the preferred choice of treatment for OSA for healthcare providers globally. The high efficacy of CPAP and other PAP devices in the treatment of sleep apnea has been instrumental in increasing the adoption of therapeutic devices globally.

However, the diagnostic device segment is expected to grow at a faster pace owing to the presence of a large pool of undiagnosed patients coupled with rising awareness about available diagnostic and treatment options for sleep apnea among the general population especially in emerging countries.

By End User Analysis

Homecare & Other Settings Dominated the Global Market in 2019

Based on end-user, the market is segmented into homecare & other settings, and sleep laboratories & clinics. Rising adoption of therapeutic devices like CPAP, oral appliances in homecare & other settings is attributed to the dominance of the segment in 2019. Increasing prevalence of sleep apnea, along with adequate reimbursement policies by the government for patients residing in such settings, are some of the major factors responsible for a higher proportion of patients being treated in these facilities.

However, sleep clinics & laboratories segment accounted for a comparatively lower share of the market owing to the less number of patients being treated completely in these facilities.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a sample

The market size in North America stood at USD 3.77 billion in 2019. The dominance of North America is due to the higher prevalence of sleep apnea and the presence of favorable reimbursement policies which has been pivotal in higher adoption of sleep apnea devices in the region. According to the American Academy of Sleep Medicine (AASM), an estimated 26% of the adult population in the U.S., was suffering from sleep apnea in 2018. On the other hand, the market of Europe is expected to grow at a significant CAGR by 2027 owing to rising awareness about sleep apnea and increasing demand for diagnostic tests coupled with the high adoption of sleep apnea devices in this region. The market of Asia Pacific is anticipated to grow at a faster pace owing to the increasing demand for devices in countries like Japan, Australia, etc. and the growing prevalence of sleep apnea in emerging countries. According to studies published, an estimated 14% adult population in India was suffering from sleep apnea. Latin America and Middle East & Africa are expected to grow at a moderate CAGR owing to the lack of awareness among the general population about sleep apnea and the presence of huge underpenetrated markets in both of these regions.

KEY INDUSTRY PLAYERS

Koninklijke Philips N.V., and ResMed Hold a Dominant Share of the Market in 2019

The market is extremely competitive and includes major players like Koninklijke Philips N.V., ResMed. The strong and diverse portfolio of these players, along with the focus on R&D to introduce new devices and strong geographical presence, are some of the factors primarily attributed to the dominance of these players in the global market. For instance, in April 2019, ResMed launched AirFit P30i, a nasal pillow CPAP mask for sleep apnea treatment in the market. Additionally, the market players are also emphasizing the introduction of technically advanced devices that will increase compliance by offering extreme comfort to the patient. For instance, in October 2018, Beddr (Hancock Medical Inc.) introduced the Sleep Tuner - a sensor worn on the forehead of a sleep apnea patient to monitor breathing during sleep. Thus, increasing advances and innovations by market players is expected to increase the adoption of sleep apnea devices in the forecast period.

Other key players engaged in the market are Oventus, Cadwell Industries, Inc., Fisher & Paykel Healthcare Limited., Natus Medical Incorporated, SomnoMed, DeVilbiss Healthcare LLC, and Braebon Medical Corporation.

LIST OF KEY PLAYERS PROFILED:

• Koninklijke Philips N.V., Amsterdam, Netherlands


• Oventus, Indooroopilly, Australia


• Cadwell Industries, Inc., Kennewick, U.S.


• ResMed, San Diego, U.S.


• Fisher & Paykel Healthcare Limited, Auckland, New Zealand


• Natus Medical Incorporated, Pleasanton, U.S.


• SomnoMed, Sydney, Australia


• DeVilbiss Healthcare LLC, Pennsylvania, U.S.


• Braebon Medical Corporation, Ontario, Canada


• Other Players

KEY INDUSTRY DEVELOPMENTS:

• January 2019 – Oventus announced the launch of O2Vent Optima oral device in Australia for the treatment of patients suffering from obstructive sleep apnea (OSA).


• September 2019 – Koninklijke Philips N.V., introduced NightBalance, a prescription sleep position therapy device in the market. This device was specially designed for patients with positional obstructive sleep apnea (OSA).

REPORT COVERAGE

The sleep apnea therapeutic devices market report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over recent years.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation